Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab in Low HER2 Metastatic Breast Cancer
NCT02491892Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2003
- Primary completion
- Apr 2005
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of pertuzumab in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Objective Response Rate at 1 year. Started Feb 2003; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02491892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02491892.